Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses.
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Healthy volunteer subjects meeting eligibility criteria
Exclusion Criteria:
* Subjects with ongoing or history of disease or co-morbidities as assessed by Principal Investigator which would make them ineligible for the study
* Subjects with a history of drug and alcohol abuse
* Subjects taking medications, over the counter or herbal remedies
Primary outcome measure(s)
Incidence of adverse events — From Informed Consent through study completion, an average of 48 days Incidence of adverse events
Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days Tmax
Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days Cmax
Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days t1/2
Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days MRT
Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days. AUC0-∞
Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days AUC0-t
Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days CL/F
Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days Vz/F
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.